The PANSS: how the Positive and Negative Syndrome Scale is used

Almost every modern antipsychotic medication on the market — from clozapine through aripiprazole, lumateperone, and the newest muscarinic agents — was approved on the strength of trials that used the Positive and Negative Syndrome Scale (PANSS) as their primary outcome measure. If you have ever read a paper, a press release, or an FDA label that says something like "the treatment group decreased PANSS total by 15 points relative to placebo," this is the instrument being described. Understanding the PANSS is one of the fastest ways to read schizophrenia research with a critical eye.

Origin

The PANSS was developed by Stanley Kay, Lewis Opler, and Abraham Fiszbein and published in Schizophrenia Bulletin in 1987. It grew out of two older instruments — the Brief Psychiatric Rating Scale (BPRS) and the Psychopathology Rating Schedule — and was designed to give equal attention to both positive and negative symptoms, which was not the strength of earlier scales. The original paper is widely cited and the scale itself is now licensed through Multi-Health Systems (MHS).

What the PANSS measures

The PANSS contains 30 items, each rated by a trained clinician on a 1 (absent) to 7 (extreme) scale. They are grouped into three subscales:

• Positive scale (P1–P7) — 7 items including delusions, conceptual disorganisation, hallucinatory behaviour, excitement, grandiosity, suspiciousness/persecution, and hostility. Score range 7–49.
• Negative scale (N1–N7) — 7 items including blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. Score range 7–49.
• General psychopathology scale (G1–G16) — 16 items covering somatic concern, anxiety, guilt feelings, tension, mannerisms, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance. Score range 16–112.

The total PANSS score therefore runs from 30 to 210. The minimum of 30 reflects the fact that "absent" is scored as 1, not 0.

How the interview is conducted

A PANSS interview takes 30 to 50 minutes for a trained rater. It is a semi-structured interview, meaning that the rater follows a recommended sequence of probes but can adapt phrasing. Information from the interview is supplemented with collateral information — chart review, family report, ward observation. Each item has explicit anchor descriptions for ratings 1 through 7, which helps anchor inter-rater reliability.

For trials, raters typically complete a formal training program and demonstrate inter-rater reliability against gold-standard videotapes (often called PANSS certification). Without certification, ratings drift, and trial results become harder to interpret.

How scores are interpreted

Several thresholds are widely cited:

• "Mildly ill" — total PANSS roughly 58
• "Moderately ill" — total PANSS roughly 75
• "Markedly ill" — total PANSS roughly 95
• "Severely ill" — total PANSS roughly 116

These thresholds come from a widely cited paper by Leucht and colleagues (2005) in Neuropsychopharmacology linking PANSS to the Clinical Global Impression scale (covered in our CGI article). They are used to translate continuous PANSS change into clinically meaningful descriptors.

A common rule of thumb in trials is that a 25–30% reduction from baseline is "response" and a 50% reduction is "remission-track." Remission criteria from the Andreasen consensus (2005) ask for ratings of 3 or less on eight specific items (P1, P2, P3, N1, N4, N6, G5, G9) sustained for at least six months.

Five-factor models

Although the PANSS was designed with three subscales, factor-analytic work has consistently identified five dimensions:

1. Positive symptoms
2. Negative symptoms
3. Disorganisation / cognitive
4. Excitement / hostility
5. Depression / anxiety

The Marder five-factor model and the van der Gaag model are the most widely used. They allow researchers to look at, for example, change in disorganisation independently of positive symptoms, which the original three-subscale structure does not isolate.

Strengths

• Excellent coverage of schizophrenia phenomenology, including negative and general items often missed by the BPRS.
• Strong inter-rater reliability when raters are certified.
• Decades of accumulated normative data and trial benchmarks make new results interpretable.
• Maps cleanly to functional outcomes and to the CGI.

Limitations

• Time and training cost. Forty minutes of clinician interview plus rater certification is a heavy lift for routine clinical use.
• Negative-item ambiguity. Negative symptoms overlap heavily with depression, medication effects, and disengagement, and this can confound scores.
• Scoring floor. The minimum score of 30 is sometimes confusing — a "well" patient still scores 30, not 0. Be careful when comparing percentage reductions.
• Cultural and language drift. Translations require careful validation; not every translation has been formally validated.

Newer alternatives

Researchers concerned about the PANSS's negative-symptom limitations sometimes use newer scales such as the Brief Negative Symptom Scale (BNSS) or the Clinical Assessment Interview for Negative Symptoms (CAINS). For positive symptoms specifically, the older SAPS is still in use, particularly in research consortia. The BPRS remains popular when a shorter assessment is needed.

What the PANSS means for patients and families

You will rarely see a PANSS score on your own clinical chart — most clinicians use simpler measures. But when a treatment is described as "evidence-based" for schizophrenia, what that almost always means is "shown to reduce PANSS scores in randomised trials." Knowing that vocabulary helps when reading drug labels, news coverage, or research summaries cited by the NIMH or NICE.

How Frida thinks about it

We do not ask people to fill out a 30-item clinician-rated scale daily — that would be both clinically inappropriate and useless. Instead we use brief, validated self-report items aligned with PANSS-relevant constructs (sleep, voice frequency, suspiciousness, withdrawal, mood) and let clinicians correlate trends with PANSS at the visits where it is administered. The PANSS is the gold standard for trial evidence; daily tracking is the bridge between visits.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.